|
Originally published In Press as doi:10.1074/jbc.C100483200 on October 11, 2001
J. Biol. Chem., Vol. 276, Issue 50, 46912-46916, December 14, 2001
5'-AMP-activated Protein Kinase Phosphorylates IRS-1 on Ser-789
in Mouse C2C12 Myotubes in Response to 5-Aminoimidazole-4-carboxamide
Riboside*
Søren N.
Jakobsen §,
D. Grahame
Hardie¶,
Nick
Morrice , and
Hans E.
Tornqvist
From Diabetes Biology, Novo Nordisk A/S, Novo Alle,
2880 Bagsvaerd, Denmark and the ¶ Division of Molecular Physiology
and Medical Research Council Protein Phosphorylation Unit,
School of Life Sciences, University of Dundee, Wellcome Trust
Biocentre, Dow Street, Dundee DD1 5EH, Scotland, United
Kingdom
Received for publication, August 22, 2001, and in revised form, September 28, 2001
 |
ABSTRACT |
Exercise is known to increase insulin sensitivity
and is an effective form of treatment for the hyperglycemia observed in type 2 diabetes. Activation of 5'-AMP-activated protein kinase (AMPK)
by 5-aminoimidazole-4-carboxamide riboside (AICAR), exercise, or
electrically stimulated contraction leads to increased glucose transport in skeletal muscle. Here we report the first evidence of a
direct interaction between AMPK and the most upstream component of the
insulin-signaling cascade, insulin receptor substrate-1 (IRS-1). We
find that AMPK rapidly phosphorylates IRS-1 on Ser-789 in cell-free
assays as well as in mouse C2C12 myotubes incubated with AICAR. In the
C2C12 myotubes activation of AMPK by AICAR matched the phosphorylation
of IRS-1 on Ser-789. This phosphorylation correlates with a 65%
increase in insulin-stimulated IRS-1-associated phosphatidylinositol
3-kinase activity in C2C12 myotubes preincubated with AICAR. The
binding of phosphatidylinositol 3-kinase to IRS-1 was not affected
by AICAR. These results demonstrate the existence of an interaction
between AMPK and early insulin signaling that could be of importance to
our understanding of the potentiating effects of exercise on insulin signaling.
 |
INTRODUCTION |
Both exercise and insulin stimulate glucose transport in skeletal
muscle (1, 2). Activation of the
IRS-11/PI 3-kinase axis is an
absolute requirement for the effects mediated by insulin (3). In the
absence of insulin, in vitro contraction of isolated
skeletal muscle can increase glucose transport, suggesting that this
stimulus uses a mechanism distinct from that of insulin (1, 4).
However, in animals (5) and in humans (6), there appears to be a
requirement for the presence of insulin to obtain fully stimulated
glucose uptake in muscle following exercise. The question as to whether
exercise mediates muscle glucose uptake completely independently of
insulin or whether exercise and insulin have a common interaction point
in vivo is therefore still unresolved.
Studies from several laboratories have suggested that AMPK is a major
mediator of contraction-induced glucose uptake in skeletal muscle based
on the observation that AMPK activity is rapidly elevated by exercise
or electrically stimulated contraction (7, 8). In addition, AICAR, a
cell-permeable activator of AMPK (9), stimulates glucose uptake in
perfused and isolated muscle (10, 11). Initially AMPK was found to
phosphorylate and inactivate 3-hydroxy-3-methylglutaryl-CoA reductase.
Later AMPK was demonstrated to modulate a number of key enzymes in
energy-regulating metabolic processes including fatty acid and
cholesterol metabolism, another aspect of the cellular response to
energy demand that is highly regulated by insulin (12). However, direct
cross-talk between AMPK and the most central axis of insulin signaling
has not yet been demonstrated.
The insulin receptor substrate IRS-1 contains multiple potential
tyrosine phosphorylation sites in consensus motifs recognized by the
insulin receptor tyrosine kinase (13). A number of proteins including
the PI 3-kinase can bind to these tyrosine phosphorylation sites via
their respective Src homology 2 domains (14). In addition, IRS-1
contains a large number of potential serine and threonine phosphorylation sites (15). Relatively little is known about the
protein-serine/threonine kinases that act on IRS-1, and the mechanisms
by which insulin signaling is influenced by serine phosphorylation of
IRS-1 are not yet well understood (16-21).
Here we provide the first evidence for a direct interaction between
AMPK and the most immediate insulin-signaling events by identifying
Ser-789 on IRS-1 as a specific phosphorylation site for AMPK. Our
results from C2C12 myotubes stimulated with AICAR suggest the existence
of a close interaction between AMPK and early insulin signaling that
could be of importance to the potentiating effects of exercise on the
metabolic effect of insulin.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Human insulin was from Novo Nordisk (Bagsvaerd,
Denmark). [ -32P]ATP was obtained from Amersham
Pharmacia Biotech. Monoclonal mouse anti-phosphotyrosine antibody PY100
was from Cell Signal Technology. Rat recombinant IRS-1 protein,
anti-IRS-1, anti-p85, and anti-phosphoserine 473-Akt antibodies
were from Upstate Biotechnology. Production of anti-phosphothreonine
172-AMPK, anti-AMPK 1, and anti-AMPK 2 antibodies and purified AMPK
and SAMS peptide has been described elsewhere (22-24). A sheep
was immunized with a keyhole limpet hemocyanin-conjugated
phosphopeptide, LRLSSSpSGRLR where Sp = phosphoserine, corresponding to amino acids 784-794 on rat
IRS-1. The Ser(P)-789 phospho-specific antibodies were collected
by affinity purification of the antiserum by sequential chromatographies on LRLSSSpSGRLR-CH-Sepharose and
LRLSSSSGRLR-CH-Sepharose (CH-Sepharose from Amersham Pharmacia
Biotech). Sequencing grade trypsin, endoproteinase Glu-C, and Complete
Protease Inhibitor Mixture were from Roche Molecular Biochemicals.
Other chemicals were obtained from Sigma Chemical Co. The peptide
LRLSSSpSGRLR corresponding to amino acids 784-794 in rat
IRS-1 was synthesized by Dr. G. Bloomberg, University of Bristol.
Treatment of Cells--
Mouse C2C12 myoblasts (ATCC) were
maintained in Dulbecco's modified Eagle's medium (DMEM), 4500 mg/liter glucose supplemented with 10% fetal calf serum, 50 units/ml
penicillin, and 50 µg/ml streptomycin. Confluent cells were
differentiated in DMEM containing 2% horse serum and fused into
myotubes after 4 days. Before experiments cells were starved for 3 h in serum-free DMEM and then incubated with 100 nM
wortmannin (35 min), 0.5 mM AICAR (30 min), and 10 nM insulin (10 min) alone or in combinations. Wortmannin
was included 5 min prior to AICAR and 25 min prior to insulin. AICAR
was included 20 min prior to insulin stimulation. Cells were lysed on
ice and either subjected to subcellular fractionation as described
below or lysed as total cell lysate including 1% Triton X-100 in the lysis buffer (20 mM Tris acetate, pH 7.0, 270 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 50 µM NaF,
5 mM sodium pyrophosphate, 10 mM sodium
-glycerophosphate, 1 mM benzamidine, 4 µg/ml
leupeptin, 4 µg/ml aprotinin, 0.2 mM
4-(2-aminoethyl)benzenesulfonyl fluoride).
Subcellular Fractionation of Cell Lysates--
C2C12 myotubes
were fractionated following a procedure simplified from that described
by Clark et al. (25). Cells were lysed in cold lysis buffer,
without Triton X-100, by passing 12 times through a 25-gauge
needle. Lysates were centrifuged for 20 min at 38,000 × g to remove plasma membranes and high-density microsomes. The resultant supernatant was centrifuged for 75 min at 170,000 × g to give a pellet (dissolved in lysis buffer) designated
high-speed pellet and a supernatant designated cytosol.
Immunoblot Analysis--
Total cell lysate and high-speed pellet
protein was subjected to SDS-PAGE and immunoblotted with the indicated
antibodies (1:1000 dilution) followed by detection using enhanced
chemiluminescence (ECL, Amersham Pharmacia Biotech). Membranes were
routinely stripped and reblotted with a second primary antibody.
In Vitro AMPK Assay--
Rat recombinant IRS-1 protein was
phosphorylated in vitro by AMPK, purified from rat liver as
described previously (26). The reactions were carried out on 0.4 µg
of IRS-1 in AMPK assay buffer (50 mM Hepes, pH 7.2, 1 mM dithiothreitol, 0.2 mM AMP, 0.02% Brij-35,
Complete Protease Inhibitor Mixture (1:50 dilution)), 10 mM
magnesium acetate, 100 µM
[ -32P]ATP (specific activity of 106
cpm/nmol) using 1 unit/ml AMPK (1 unit of AMPK phosphorylates 1 nmol of
SAMS peptide/min at 30 °C) in a final volume of 30 µl at 30 °C
for various times. Following SDS-PAGE the IRS-1 bands were cut out, and
radioactivity was measured by liquid scintillation counting. The
Km and Vmax values for AMPK
activity toward the IRS-1 peptide (LRLSSSSGRLR), its corresponding
phosphopeptide (LRLSSSpSGRLR), and the SAMS peptide
(HMRSAMSGLHLVKRR) were determined with increasing concentrations of
substrate peptide in a total volume of 20 µl under the
above-described conditions After 20 min the reaction was stopped and
spotted onto phosphocellulose Whatman P81 paper that was washed with 75 mM phosphoric acid and counted by Cerenkov counting.
Two-dimensional Phosphopeptide Mapping--
Phosphorylated IRS-1
was separated from AMPK by SDS-PAGE, cut out from the dried gel, and
washed sequentially in water; 50% acetonitrile, H2O; 100 mM NH4HCO3, and 50 mM
NH4HCO3, 50% acetonitrile followed by
in-gel digestion with 0.2 µg/ml of sequencing grade trypsin in 50 mM NH4HCO3 overnight at 37 °C.
32P-Radiolabeled tryptic peptides were recovered by
extracting with 50% acetonitrile, 50 mM
NH4HCO3 and subjected to two-dimensional TLE/TLC (27). Radioactive phosphopeptides were detected by
PhosphorImager technology.
Determination of Phosphorylated Site on IRS-1
Peptides--
IRS-1-derived tryptic 32P-peptides were
lyophilized, reconstituted in 50% acetonitrile, 0.1% trifluoroacetic
acid, loaded onto a C18 reverse phase peptide/protein column (Vydac C18
4.6 × 250 mm, catalog no. 218TP54), and separated against an
acetonitrile gradient in 0.1% trifluoroacetic acid at a flow rate of
300 µl/min. 32P-Labeled phosphopeptides were detected by
liquid scintillation counting of the 0.4-ml fractions collected (28).
32P-Labeled IRS-1 phosphopeptides isolated by HPLC
fractionation were subjected to phosphoamino acid analysis (27). The
site of phosphorylation was determined by solid phase Edman degradation of the 32P-labeled tryptic IRS-1 phosphopeptides (29).
IRS-1 digested with 0.2 µg/ml endopeptidase Glu-C in 50 mM ammonium bicarbonate overnight at 37 °C was analyzed
by the same procedure as for trypsin-digested IRS-1.
Determination of IRS-1-associated PI 3-Kinase
Activity--
IRS-1 and p85-associated IRS-1 was immunoprecipitated
from cell lysates (250 µg of protein) using 1.5 µg of anti-IRS-1 or anti-p85 antibodies, respectively, and collected with protein A-Sepharose beads. IRS-1-associated PI 3-kinase activity in the immunocomplex was measured and detected as described previously (30).
 |
RESULTS |
AMPK Phosphorylates IRS-1 on Ser-789 in Vitro--
From the
screening of a number of purified kinases for their ability to
phosphorylate IRS-1, purified AMPK from rat liver was found to rapidly
phosphorylate recombinant rat IRS-1 in vitro with a
stoichiometry of phosphorylation reaching 0.4 mol of phosphate/mol of
IRS-1 (Fig. 1A).
Two-dimensional tryptic phosphopeptide mapping of IRS-1 established
that the phosphate was primarily incorporated into one single tryptic
peptide (Fig. 1B, inset). For the identification of the site phosphorylated on IRS-1 by AMPK we resolved the tryptic digest of IRS-1 by reverse phase HPLC and detected a single peak of
radioactivity (Fig. 1B). This HPLC fraction was first
subjected to solid phase Edman degradation with release of
radioactivity during cycle 4 (Fig. 1C). Phosphoamino acid
analysis showed phosphorylation exclusively on serine (Fig.
1D).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
AMPK phosphorylates IRS-1 on Ser-789 in
vitro. A, recombinant IRS-1 (3.5 pmol) was
incubated with purified AMPK for various times in the presence of 100 µM Mg[ -32P]ATP and separated by
SDS-PAGE. Radioactivity incorporated into IRS-1 was determined by
liquid scintillation counting, and the stoichiometry in phosphorylation
was assessed knowing the specific activity of the
[ -32P]ATP used. The bottom panel shows the
autoradiogram from one representative experiment, whereas the graph at
the top shows pooled data from four experiments.
P, phosphate. B, recombinant IRS-1, maximally
phosphorylated by AMPK (45 min), was separated from AMPK by SDS-PAGE
and digested with trypsin. The recovered 32P-radiolabeled
tryptic peptide mixture was either separated by reverse phase HPLC and
fractions were counted by liquid scintillation or separated by TLE/TLC
and detected by PhosphorImager technology (inset).
C, the single reverse phase HPLC fraction of tryptic IRS-1
peptides containing radioactivity was subjected to solid phase Edman
sequencing, and radioactivity released at each cycle was counted by
liquid scintillation. D, phosphoamino acid analysis of the
isolated 32P-radiolabeled tryptic peptide. pS,
phosphoserine; pT, phosphothreonine; pY,
phosphotyrosine. E, kinetics in AMPK activity toward the
IRS-1 peptide (LRLSSSSGRLR) ( ), its corresponding phosphopeptide
(LRLSSSpSGRLR) ( ) and the SAMS peptide (HMRSAMSGLHLVKRR)
( ) was determined. Results are presented as means of one
representative triplicate assay ± S.D. Km and
Vmax values were determined by nonlinear
regression using GraphPad Prism 3 software.
|
|
Assuming no missed cleavages, trypsin would be expected to generate
eight peptides from IRS-1 containing a serine residue 4 amino acids
distal to the cleavage site. The consensus recognition motif for AMPK
is Hyd-(X,Basic)XX(S/T)XXX-Hyd (where
Hyd = M, L, I, F, or V and Basic = R > K > H
(31)). A search of the rat IRS-1 sequence using this motif with
the program Findpatterns (from the GCG suite (32)) revealed a single
fit to this motif, i.e. Ser-789. This sequence, which is
conserved in the human, and the mouse IRS-1 sequence also contain a
histidine 6 residues N-terminal to the phosphorylated serine. A basic
residue at this position is an additional positive determinant for
AMPK.2 This predicted
phosphorylation site at Ser-789 was confirmed by digesting IRS-1 with
endopeptidase Glu-C. The HPLC separation of AMPK-phosphorylated IRS-1
digested with endopeptidase Glu-C gave rise to two peaks containing
phosphorylated serine that eluted at similar times. Both peaks gave
release of phosphate on Edman degradation cycle 12 (data not shown).
Ser-789 is the only serine in the rat IRS-1 sequence that is 4 amino
acids distal to a trypsin protease cleavage site (residues 786-793)
and 12 amino acids distal to an endopeptidase Glu-C cleavage site
(residues 778-800/801). In addition AMPK readily phosphorylated the
synthetic dephosphopeptide but not the phosphopeptide corresponding to
the amino acid sequence 784-794 of rat IRS-1 (Fig. 1E). The
dephosphopeptide was a good substrate for AMPK with a
Km of 33 ± 5 µM compared with a
Km of 49 ± 4 µM for the SAMS
peptide, the standard substrate for AMPK. AMPK had a similar
Vmax toward both peptides. On the basis of these
data we conclude that AMPK readily phosphorylates IRS-1 on Ser-789
in vitro.
AMPK Phosphorylates IRS-1 on Ser-789 in Intact Cells--
To
determine whether AMPK phosphorylates IRS-1 on Ser-789 in intact cells,
we raised phospho-specific antibodies in sheep against the
phosphopeptide LRLSSSpSGRLR. This antibody recognized rat
recombinant IRS-1 that had been incubated with MgATP in the presence
but not the absence of AMPK (not shown). Incubation of the Ser(P)-789
antibody with the LRLSSSpSGRLR peptide used to raise the
antibody abolished its recognition of IRS-1 phosphorylated by AMPK (not
shown). Whether IRS-1 is phosphorylated on Ser-789 in intact cells was
investigated in mouse C2C12 myotubes stimulated with AICAR. IRS-1 in
the high-speed pellet fraction of untreated C2C12 myotubes did not
react with the Ser(P)-789 antibody by immunoblot analysis. However,
after incubation of the cells with 0.5 mM AICAR for 5-120
min, IRS-1 from C2C12 myotubes was clearly detected using the
Ser(P)-789-specific antibody for immunoblotting (Fig. 2A). Phosphorylation on
Ser-789 of IRS-1 was also found in primary rat hepatocytes and in
primary rat adipocytes after stimulation with AICAR (data not shown).
To estimate the extent of Ser-789 phosphorylation on IRS-1 in C2C12
myotubes we analyzed, by Western blot analysis using the
anti-Ser(P)-789 antibody, samples from AICAR-treated C2C12 myotubes
together with recombinant IRS-1 phosphorylated by purified AMPK
in vitro. Phosphorylation of IRS-1 on Ser-789 in C2C12
myotubes appeared comparable to or greater than the stoichiometry of
phosphorylation achieved in vitro (Fig. 2B).
Insulin did not induce phosphorylation on Ser-789, and phosphorylation
induced by AICAR could not be inhibited by wortmannin, demonstrating
that the phosphorylation on Ser-789 does not occur through
phosphorylation by Akt or other insulin-activated kinases (Fig.
3). AMPK 1 activation in C2C12
myotubes, judged by assessment of Thr-172 phosphorylation using an
anti-Thr(P)-172 antibody, was induced by AICAR treatment and not
by insulin stimulation (Fig. 3). AMPK 2 activation by AICAR was also
detected but with a much weaker signal than AMPK 1 (data not shown).
No modulation of insulin-induced phosphorylation of IRS-1 on tyrosine
or activation of Akt as judged by phosphorylation of Akt on Ser-473 was
seen in response to AICAR (Fig. 3). Total levels of IRS-1, p85 subunit
of PI 3-kinase, or Akt in the high-speed pellet were also unchanged in
response to AICAR and/or insulin (Fig. 3).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 2.
Western blot analysis of AMPK phosphorylation
of IRS-1 on Ser-789. A, C2C12 myotubes were incubated
with 0.5 mM AICAR for the times indicated, and high-speed
pellets (15 µg of protein) of cell lysates were analyzed for Ser-789
phosphorylation on IRS-1. B, Ser-789 phosphorylation in the
same samples from time 0 and 30 min were compared with Ser-789
phosphorylation of 5, 10, and 50 ng of recombinant IRS-1 that had been
incubated with MgATP in the presence (+) or absence ( ) of purified
AMPK. Samples were subjected to SDS-PAGE and probed for phosphorylation
of Ser-789 in IRS-1 by immunoblotting using anti-phospho-Ser-789
(pS789) antibody and reprobed using a nonphospho-specific
anti-IRS-1 antibody to allow comparison of the amounts of IRS-1 loaded
onto the gel.
|
|

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of Ser-789 phosphorylation on
tyrosine phosphorylation of IRS-1 in C2C12 myotubes. C2C12
myotubes were stimulated with insulin (10 nM) and/or AICAR
(0.5 mM) in the presence or absence of wortmannin as
indicated, and cell extracts were analyzed by immunoblot analysis.
High-speed pellet fractions (15 µg of protein) or total cell lysate
(25 µg of protein, AMPK only) were subjected to SDS-PAGE and
immunoblotted using selective Ser(P)-789-IRS-1, phosphoserine 473-Akt
(pS473Akt), or phosphothreonine 172-AMPK
(pT172-AMPK) antibodies as indicated. Blots were then
stripped and reblotted as appropriate with anti-Tyr(P), anti-IRS-1,
anti-p85, anti-Akt, and anti-AMPK 1 antibodies as indicated.
pY, phosphotyrosine.
|
|
IRS-1-associated PI 3-Kinase Activity--
To further investigate
whether phosphorylation of Ser-789 on IRS-1 induces changes in the
formation or activity of the IRS-1-Tyr(P)·p85-PI 3-kinase
complex we measured the binding and activation of PI 3-kinase in IRS-1
immunoprecipitates of whole C2C12 cell extracts treated with insulin
and/or AICAR. In the absence of insulin no change in p85 or PI 3-kinase
activity associated with IRS-1 was seen. In the presence of insulin
AICAR induced a significant 65% additional increase in
IRS-1-associated PI 3-kinase activity, whereas no change in IRS-1
tyrosine phosphorylation or binding of p85 to IRS-1 (measured as IRS-1
in p85 immunoprecipitates) was detected (Fig.
4). This synergistic increase in
IRS-1-associated PI 3-kinase activity was sustained for up to 60 min
(data not shown). AICAR on its own did not increase PI 3-kinase
activity.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 4.
IRS-1-associated PI 3-kinase activity
following insulin and AICAR stimulation. C2C12 myotubes were
stimulated with insulin (10 nM) and/or AICAR (0.5 mM), and IRS-1-associated PI 3-kinase activity in
anti-IRS-1 immunoprecipitates from total cell lysates was measured
using phosphatidylinositol as substrate. For comparison tyrosine
phosphorylation of IRS-1 in the IRS-1 immunoprecipitate and IRS-1
associated with the p85 subunit of PI 3-kinase in an anti-p85
immunoprecipitate of the total cell extracts was analyzed by
immunoblotting using anti-phosphotyrosine (pY) and
anti-IRS-1 antibodies, respectively (upper panels). For
estimating PI 3-kinase activity the 32P radioactivity
incorporated into PI3P was determined by thin-layer chromatography and
PhosphorImager analysis of the TLC plates. One representative
experiment of TLC-resolved PI332P spots is shown. The
combined results of four independent experiments are presented as -fold
radioactivity in PI332P relative to that in the
insulin-stimulated sample ± S.E.
|
|
 |
DISCUSSION |
By taking an in vitro based approach to screen for
purified kinases that demonstrate activity toward IRS-1 we identified
AMPK as a potential modifier of insulin signaling through
phosphorylation of IRS-1 on Ser-789. The in vitro activity
of AMPK toward recombinant IRS-1 was directed toward a single peptide
suggesting that AMPK had a high specificity toward this sequence that
is conserved in human, rat, and mouse IRS-1. This was supported through
determination of the Km for AMPK toward the IRS-1
peptide, which showed that this primary sequence is a good substrate
compared with the SAMS peptide, a well characterized AMPK substrate. By
producing an antibody that is specific for the detection of IRS-1
phosphorylated on Ser-789 we were able to investigate the occurrence of
this phosphorylation in the intact cell by using the high-speed pellet fraction where IRS-1 is highly enriched (25). The degree of phosphorylation of IRS-1 on Ser-789 was rapid to a substantial stoichiometry with a time course consistent with previous studies of
AMPK activation by AICAR in intact cells (9). Given that AMPK
phosphorylates recombinant IRS-1 exclusively on Ser-789 in vitro, that this site appears to be an excellent substrate for AMPK, and that the same site is phosphorylated in intact cells in
response to AICAR, it is very likely that AMPK does indeed phosphorylate IRS-1 in the intact cell. We have no evidence that other
protein kinases phosphorylate the same site. If a kinase other than
AMPK is responsible, it does not appear to lie downstream of the
insulin receptor.
Previously serine phosphorylation of IRS-1 has been demonstrated to
correlate with a reduced capacity of insulin to activate PI 3-kinase
(17, 18, 20, 21). In this study we did not observe impaired insulin
signaling in C2C12 myotubes despite the observation that IRS-1 appears
to be phosphorylated on Ser-789 to a high stoichiometry following AICAR
treatment. Importantly and in contrast, we observed an increased
activity of IRS-1-associated PI 3-kinase as seen in anti-IRS-1
immunoprecipitates. Since neither insulin-induced association between
the p85 subunit of PI 3-kinase and IRS-1 nor cellular distribution of
p85, IRS-1, or IRS-1-Tyr(P) is changed by AICAR stimulation it appears
that the PI 3-kinase associated with Ser-789-phosphorylated IRS-1 is in
a more active form than the PI 3-kinase associated with IRS-1 not
phosphorylated on Ser-789. The reason why we do not see altered
insulin-stimulated Akt phosphorylation in the presence of AICAR is not
known. One explanation could be given by previous findings suggesting
that only a small amount of insulin is necessary to fully activate Akt
(33, 34).
Recently it has been reported that expression of a dominant inhibitory
mutant of AMPK in mouse muscle completely blocks the ability of AICAR
to activate hexose uptake, whereas contraction-induced hexose uptake is
only partially reduced indicating that there are at least partly
divergent pathways responsible for the effects of AICAR
versus contraction on glucose uptake (35). Partly divergent pathways for AICAR- versus contraction-induced effects on
glucose uptake could possibly explain the divergence between our
findings and the reported decrease in IRS-1-associated PI 3-kinase
activity in insulin-stimulated muscle after contraction (36, 37). Our findings that IRS-1 phosphorylation on Ser-789 also occurs in primary
rat adipocytes and in hepatocytes exposed to AICAR imply that there has
to be a stimulus for phosphorylation of Ser-789 other than contraction.
It points to the existence of a more general mechanism for
insulin-responsive cells to react to changes in ATP levels. Possibly
this includes direction of signaling via IRS-1 toward intracellular
energy-restoring processes, e.g. by increasing glucose
uptake and reducing fatty acid and cholesterol synthesis.
Several reports from studies on incubated muscles have shown that the
PI 3-kinase inhibitor wortmannin inhibits insulin-stimulated glucose
uptake but not contraction-stimulated glucose uptake (11, 38). However,
another report demonstrates that wortmannin does inhibit some of the
contraction-stimulated glucose transport in rat skeletal muscle
suggesting that the signaling pathways activated by insulin and
exercise might also converge on a common effector (39). This would
explain the circumstances where the combination of insulin and exercise
show a synergistic effect on glucose transport (5, 6).
In conclusion we suggest that phosphorylation of IRS-1 on Ser-789 by
AMPK might represent a novel mechanism for insulin-responsive cells to
react to changes in cellular energy status. This could be by directing
signaling through IRS-1 toward energy-restoring processes or via an
overall potentiating effect on insulin signaling mediated by an
increased activity of the PI 3-kinase associated with IRS-1. Exercise
could be the effect that initiates these mechanisms in muscle. We
believe this is the first report that identifies a specific serine
phosphorylation on IRS-1 that may positively affect insulin signaling.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Erica Nishimura for constructive
suggestions and comments on this manuscript. We also thank Dr. Jon
Whitehead and Professor David E. James for introducing Søren Nyboe
Jakobsen to the subcellular fractionation protocol.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 45-44424231; Fax:
45-44424858; E-mail: snyj@novonordisk.com.
Published, JBC Papers in Press, October 11, 2001, DOI 10.1074/jbc.C100483200
2
D. G. Hardie and J. W. Scott, unpublished.
 |
ABBREVIATIONS |
The abbreviations used are:
IRS-1, insulin
receptor substrate-1;
PI, phosphatidylinositol;
AMPK, 5'-AMP-activated
protein kinase;
AICAR, 5-aminoimidazole-4-carboxamide riboside;
DMEM, Dulbecco's modified Eagle's medium;
PAGE, polyacrylamide gel
electrophoresis;
TLE, thin-layer electrophoresis;
TLC, thin-layer chromatography;
HPLC, high pressure liquid chromatography;
PI3P, phosphatidylinositol 3-phosphate.
 |
REFERENCES |
| 1.
|
Nesher, R.,
Karl, I. E.,
and Kipnis, D. M.
(1985)
Am. J. Physiol.
249,
C226-C232[Abstract/Free Full Text]
|
| 2.
|
Ploug, T.,
Galbo, H.,
Vinten, J.,
Jorgensen, M.,
and Richter, E. A.
(1987)
Am. J. Physiol.
253,
E12-E20[Abstract/Free Full Text]
|
| 3.
|
Shepherd, P. R.,
Withers, D. J.,
and Siddle, K.
(1998)
Biochem. J.
333,
471-490
|
| 4.
|
Ploug, T.,
Galbo, H.,
and Richter, E. A.
(1984)
Am. J. Physiol.
247,
E726-E731[Abstract/Free Full Text]
|
| 5.
|
Vranic, M.,
Kawamori, R.,
Pek, S.,
Kovacevic, N.,
and Wrenshall, G. A.
(1976)
J. Clin. Invest.
57,
245-255
|
| 6.
|
DeFronzo, R. A.,
Ferrannini, E.,
Sato, Y.,
Felig, P.,
and Wahren, J.
(1981)
J. Clin. Invest.
68,
1468-1474
|
| 7.
|
Winder, W. W.,
and Hardie, D. G.
(1996)
Am. J. Physiol.
270,
E299-E304[Abstract/Free Full Text]
|
| 8.
|
Vavvas, D.,
Apazidis, A.,
Saha, A. K.,
Gamble, J.,
Patel, A.,
Kemp, B. E.,
Witters, L. A.,
and Ruderman, N. B.
(1997)
J. Biol. Chem.
272,
13255-13261[Abstract/Free Full Text]
|
| 9.
|
Corton, J. M.,
Gillespie, J. G.,
Hawley, S. A.,
and Hardie, D. G.
(1995)
Eur. J. Biochem.
229,
558-565[Medline]
[Order article via Infotrieve]
|
| 10.
|
Merrill, G. F.,
Kurth, E. J.,
Hardie, D. G.,
and Winder, W. W.
(1997)
Am. J. Physiol.
273,
E1107-E1112
|
| 11.
|
Hayashi, T.,
Hirshman, M. F.,
Kurth, E. J.,
Winder, W. W.,
and Goodyear, L. J.
(1998)
Diabetes
47,
1369-1373[Abstract]
|
| 12.
|
Hardie, D. G.,
and Carling, D.
(1997)
Eur. J. Biochem.
246,
259-273[Medline]
[Order article via Infotrieve]
|
| 13.
|
Shoelson, S. E.,
Chatterjee, S.,
Chaudhuri, M.,
and White, M. F.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
2027-2031[Abstract/Free Full Text]
|
| 14.
|
Yenush, L.,
and White, M. F.
(1997)
Bioessays
19,
491-500[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Sun, X. J.,
Rothenberg, P.,
Kahn, C. R.,
Backer, J. M.,
Araki, E.,
Wilden, P. A.,
Cahill, D. A.,
Goldstein, B. J.,
and White, M. F.
(1991)
Nature
352,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Tanasijevic, M. J.,
Myers, M. G., Jr.,
Thoma, R. S.,
Crimmins, D. L.,
White, M. F.,
and Sacks, D. B.
(1993)
J. Biol. Chem.
268,
18157-18166[Abstract/Free Full Text]
|
| 17.
|
De Fea, K.,
and Roth, R. A.
(1997)
J. Biol. Chem.
272,
31400-31406[Abstract/Free Full Text]
|
| 18.
|
Eldar-Finkelman, H.,
and Krebs, E. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
9660-9664[Abstract/Free Full Text]
|
| 19.
|
Li, J.,
DeFea, K.,
and Roth, R. A.
(1999)
J. Biol. Chem.
274,
9351-9356[Abstract/Free Full Text]
|
| 20.
|
Ravichandran, L. V.,
Esposito, D. L.,
Chen, J.,
and Quon, M. J.
(2001)
J. Biol. Chem.
276,
3543-3549[Abstract/Free Full Text]
|
| 21.
|
Aguirre, V.,
Uchida, T.,
Yenush, L.,
Davis, R.,
and White, M. F.
(2000)
J. Biol. Chem.
275,
9047-9054[Abstract/Free Full Text]
|
| 22.
|
Sugden, C.,
Crawford, R. M.,
Halford, N. G.,
and Hardie, D. G.
(1999)
Plant J.
19,
433-439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Woods, A.,
Salt, I.,
Scott, J.,
Hardie, D. G.,
and Carling, D.
(1996)
FEBS Lett.
397,
347-351[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Hawley, S. A.,
Davison, M.,
Woods, A.,
Davies, S. P.,
Beri, R. K.,
Carling, D.,
and Hardie, D. G.
(1996)
J. Biol. Chem.
271,
27879-27887[Abstract/Free Full Text]
|
| 25.
|
Clark, S. F.,
Martin, S.,
Carozzi, A. J.,
Hill, M. M.,
and James, D. E.
(1998)
J. Cell Biol.
140,
1211-1225[Abstract/Free Full Text]
|
| 26.
|
Carling, D.,
Clarke, P. R.,
Zammit, V. A.,
and Hardie, D. G.
(1989)
Eur. J. Biochem.
186,
129-136[Medline]
[Order article via Infotrieve]
|
| 27.
|
Boyle, W. J.,
van der, G. P.,
and Hunter, T.
(1991)
Methods Enzymol.
201,
110-149[Medline]
[Order article via Infotrieve]
|
| 28.
|
Scheper, G. C.,
Morrice, N. A.,
Kleijn, M.,
and Proud, C. G.
(2001)
Mol. Cell. Biol.
21,
743-754[Abstract/Free Full Text]
|
| 29.
|
Stokoe, D.,
Campbell, D. G.,
Nakielny, S.,
Hidaka, H.,
Leevers, S. J.,
Marshall, C.,
and Cohen, P.
(1992)
EMBO J.
11,
3985-3994[Medline]
[Order article via Infotrieve]
|
| 30.
|
Ridderstrale, M.,
Degerman, E.,
and Tornqvist, H.
(1995)
J. Biol. Chem.
270,
3471-3474[Abstract/Free Full Text]
|
| 31.
|
Dale, S.,
Wilson, W. A.,
Edelman, A. M.,
and Hardie, D. G.
(1995)
FEBS Lett.
361,
191-195[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Devereux, J.,
Haeberli, P.,
and Smithies, O.
(1984)
Nucleic Acids Res.
12,
387-395
|
| 33.
|
Kim, Y. B.,
Nikoulina, S. E.,
Ciaraldi, T. P.,
Henry, R. R.,
and Kahn, B. B.
(1999)
J. Clin. Invest.
104,
733-741[Medline]
[Order article via Infotrieve]
|
| 34.
|
Ceresa, B. P.,
Kao, A. W.,
Santeler, S. R.,
and Pessin, J. E.
(1998)
Mol. Cell. Biol.
18,
3862-3870[Abstract/Free Full Text]
|
| 35.
|
Mu, J.,
Brozinick, J. T.,
Valladares, O.,
Bucan, M.,
and Birnbaum, M. J.
(2001)
Mol. Cell
7,
1085-1094[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Whitehead, J. P.,
Soos, M. A.,
Aslesen, R.,
O'Rahilly, S.,
and Jensen, J.
(2000)
Biochem. J.
349,
775-781
|
| 37.
|
Wojtaszewski, J. F.,
Hansen, B. F.,
Kiens, B.,
and Richter, E. A.
(1997)
Diabetes
46,
1775-1781[Abstract]
|
| 38.
|
Lund, S.,
Holman, G. D.,
Schmitz, O.,
and Pedersen, O.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
5817-5821[Abstract/Free Full Text]
|
| 39.
|
Wojtaszewski, J. F.,
Hansen, B. F.,
Urso, B.,
and Richter, E. A.
(1996)
J. Appl. Physiol.
81,
1501-1509[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. R. Steinberg and B. E. Kemp
AMPK in Health and Disease
Physiol Rev,
July 1, 2009;
89(3):
1025 - 1078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Y.C. Yuen, R. M. Dwyer, V. B. Matthews, L. Zhang, B. G. Drew, B. Neill, B. A. Kingwell, M. G. Clark, S. Rattigan, and M. A. Febbraio
Interleukin-6 Attenuates Insulin-Mediated Increases in Endothelial Cell Signaling but Augments Skeletal Muscle Insulin Action via Differential Effects on Tumor Necrosis Factor-{alpha} Expression
Diabetes,
May 1, 2009;
58(5):
1086 - 1095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Boura-Halfon and Y. Zick
Phosphorylation of IRS proteins, insulin action, and insulin resistance
Am J Physiol Endocrinol Metab,
April 1, 2009;
296(4):
E581 - E591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Weigert, M. Kron, H. Kalbacher, A. K. Pohl, H. Runge, H.-U. Haring, E. Schleicher, and R. Lehmann
Interplay and Effects of Temporal Changes in the Phosphorylation State of Serine-302, -307, and -318 of Insulin Receptor Substrate-1 on Insulin Action in Skeletal Muscle Cells
Mol. Endocrinol.,
December 1, 2008;
22(12):
2729 - 2740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Pedersen and M. A. Febbraio
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Physiol Rev,
October 1, 2008;
88(4):
1379 - 1406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Zhu, B. Han, J. Tong, C. Ma, J. M. Kimzey, K. R. Underwood, Y. Xiao, B. W. Hess, S. P. Ford, P. W. Nathanielsz, et al.
AMP-activated protein kinase signalling pathways are down regulated and skeletal muscle development impaired in fetuses of obese, over-nourished sheep
J. Physiol.,
May 15, 2008;
586(10):
2651 - 2664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Park, S. M. Hong, S. R. Sung, and H. K. Jung
Long-Term Effects of Central Leptin and Resistin on Body Weight, Insulin Resistance, and {beta}-Cell Function and Mass by the Modulation of Hypothalamic Leptin and Insulin Signaling
Endocrinology,
February 1, 2008;
149(2):
445 - 454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Frosig, M. P. Sajan, S. J. Maarbjerg, N. Brandt, C. Roepstorff, J. F. P. Wojtaszewski, B. Kiens, R. V. Farese, and E. A. Richter
Exercise improves phosphatidylinositol-3,4,5-trisphosphate responsiveness of atypical protein kinase C and interacts with insulin signalling to peptide elongation in human skeletal muscle
J. Physiol.,
August 1, 2007;
582(3):
1289 - 1301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Herschkovitz, Y.-F. Liu, E. Ilan, D. Ronen, S. Boura-Halfon, and Y. Zick
Common Inhibitory Serine Sites Phosphorylated by IRS-1 Kinases, Triggered by Insulin and Inducers of Insulin Resistance
J. Biol. Chem.,
June 22, 2007;
282(25):
18018 - 18027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tzatsos and P. N. Tsichlis
Energy Depletion Inhibits Phosphatidylinositol 3-Kinase/Akt Signaling and Induces Apoptosis via AMP-activated Protein Kinase-dependent Phosphorylation of IRS-1 at Ser-794
J. Biol. Chem.,
June 22, 2007;
282(25):
18069 - 18082.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Naimi, N. Gautier, C. Chaussade, A. M. Valverde, D. Accili, and E. Van Obberghen
Nuclear Forkhead Box O1 Controls and Integrates Key Signaling Pathways in Hepatocytes
Endocrinology,
May 1, 2007;
148(5):
2424 - 2434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Kang, A. L. Brown, and J. H. Chung
Oxygen Tension Regulates the Stability of Insulin Receptor Substrate-1 (IRS-1) through Caspase-mediated Cleavage
J. Biol. Chem.,
March 2, 2007;
282(9):
6090 - 6097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. LaRosa and S. M. Downs
Meiotic Induction by Heat Stress in Mouse Oocytes: Involvement of AMP-Activated Protein Kinase and MAPK Family Members
Biol Reprod,
March 1, 2007;
76(3):
476 - 486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Towler and D. G. Hardie
AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
Circ. Res.,
February 16, 2007;
100(3):
328 - 341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Bogoyevitch and B. Kobe
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases
Microbiol. Mol. Biol. Rev.,
December 1, 2006;
70(4):
1061 - 1095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Morino, K. F. Petersen, and G. I. Shulman
Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction
Diabetes,
December 1, 2006;
55(Supplement_2):
S9 - S15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Koh, D. E. Arnolds, N. Fujii, T. T. Tran, M. J. Rogers, N. Jessen, Y. Li, C. W. Liew, R. C. Ho, M. F. Hirshman, et al.
Skeletal Muscle-Selective Knockout of LKB1 Increases Insulin Sensitivity, Improves Glucose Homeostasis, and Decreases TRB3
Mol. Cell. Biol.,
November 15, 2006;
26(22):
8217 - 8227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Fediuc, M. P. Gaidhu, and R. B. Ceddia
Inhibition of Insulin-Stimulated Glycogen Synthesis by 5-Aminoimidasole-4-Carboxamide-1-{beta}-D-Ribofuranoside-Induced Adenosine 5'-Monophosphate-Activated Protein Kinase Activation: Interactions with Akt, Glycogen Synthase Kinase 3-3{alpha}/{beta}, and Glycogen Synthase in Isolated Rat Soleus Muscle
Endocrinology,
November 1, 2006;
147(11):
5170 - 5177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fujii, N. Jessen, and L. J. Goodyear
AMP-activated protein kinase and the regulation of glucose transport
Am J Physiol Endocrinol Metab,
November 1, 2006;
291(5):
E867 - E877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Carey, G. R. Steinberg, S. L. Macaulay, W. G. Thomas, A. G. Holmes, G. Ramm, O. Prelovsek, C. Hohnen-Behrens, M. J. Watt, D. E. James, et al.
Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase.
Diabetes,
October 1, 2006;
55(10):
2688 - 2697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Berasi, C. Huard, D. Li, H. H. Shih, Y. Sun, W. Zhong, J. E. Paulsen, E. L. Brown, R. E. Gimeno, and R. V. Martinez
Inhibition of Gluconeogenesis through Transcriptional Activation of EGR1 and DUSP4 by AMP-activated Kinase
J. Biol. Chem.,
September 15, 2006;
281(37):
27167 - 27177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bertrand, A. Ginion, C. Beauloye, A. D. Hebert, B. Guigas, L. Hue, and J.-L. Vanoverschelde
AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B
Am J Physiol Heart Circ Physiol,
July 1, 2006;
291(1):
H239 - H250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Weigert, A. M. Hennige, R. Lehmann, K. Brodbeck, F. Baumgartner, M. Schauble, H. U. Haring, and E. D. Schleicher
Direct Cross-talk of Interleukin-6 and Insulin Signal Transduction via Insulin Receptor Substrate-1 in Skeletal Muscle Cells
J. Biol. Chem.,
March 17, 2006;
281(11):
7060 - 7067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Lessard, Z.-P. Chen, M. J. Watt, M. Hashem, J. J. Reid, M. A. Febbraio, B. E. Kemp, and J. A. Hawley
Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle
Am J Physiol Endocrinol Metab,
February 1, 2006;
290(2):
E251 - E257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Weigert, A. M. Hennige, T. Brischmann, A. Beck, K. Moeschel, M. Schauble, K. Brodbeck, H.-U. Haring, E. D. Schleicher, and R. Lehmann
The Phosphorylation of Ser318 of Insulin Receptor Substrate 1 Is Not per se Inhibitory in Skeletal Muscle Cells but Is Necessary to Trigger the Attenuation of the Insulin-stimulated Signal
J. Biol. Chem.,
November 11, 2005;
280(45):
37393 - 37399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Smith, P. B. Patil, and J. S. Fisher
AICAR and hyperosmotic stress increase insulin-stimulated glucose transport
J Appl Physiol,
September 1, 2005;
99(3):
877 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. L. Thong, C. B. Dugani, and A. Klip
Turning Signals On and Off: GLUT4 Traffic in the Insulin-Signaling Highway
Physiology,
August 1, 2005;
20(4):
271 - 284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pelletier, E. Joly, M. Prentki, and L. Coderre
Adenosine 5'-Monophosphate-Activated Protein Kinase and p38 Mitogen-Activated Protein Kinase Participate in the Stimulation of Glucose Uptake by Dinitrophenol in Adult Cardiomyocytes
Endocrinology,
May 1, 2005;
146(5):
2285 - 2294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Reiter, D. R. Bolster, S. J. Crozier, S. R. Kimball, and L. S. Jefferson
Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside
Am J Physiol Endocrinol Metab,
May 1, 2005;
288(5):
E980 - E988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Liberman and H. Eldar-Finkelman
Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling
J. Biol. Chem.,
February 11, 2005;
280(6):
4422 - 4428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. D. Werner, J. Lee, L. Hansen, M. Yuan, and S. E. Shoelson
Insulin Resistance Due to Phosphorylation of Insulin Receptor Substrate-1 at Serine 302
J. Biol. Chem.,
August 20, 2004;
279(34):
35298 - 35305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Giraud, R. Leshan, Y.-H. Lee, and M. F. White
Nutrient-dependent and Insulin-stimulated Phosphorylation of Insulin Receptor Substrate-1 on Serine 302 Correlates with Increased Insulin Signaling
J. Biol. Chem.,
January 30, 2004;
279(5):
3447 - 3454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ouchi, H. Kobayashi, S. Kihara, M. Kumada, K. Sato, T. Inoue, T. Funahashi, and K. Walsh
Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells
J. Biol. Chem.,
January 9, 2004;
279(2):
1304 - 1309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barthel and D. Schmoll
Novel concepts in insulin regulation of hepatic gluconeogenesis
Am J Physiol Endocrinol Metab,
October 1, 2003;
285(4):
E685 - E692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Horike, H. Takemori, Y. Katoh, J. Doi, L. Min, T. Asano, X. J. Sun, H. Yamamoto, S. Kasayama, M. Muraoka, et al.
Adipose-specific Expression, Phosphorylation of Ser794 in Insulin Receptor Substrate-1, and Activation in Diabetic Animals of Salt-inducible Kinase-2
J. Biol. Chem.,
May 9, 2003;
278(20):
18440 - 18447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Jessen, R. Pold, E. S. Buhl, L. S. Jensen, O. Schmitz, and S. Lund
Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles
J Appl Physiol,
April 1, 2003;
94(4):
1373 - 1379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Lee, J. Giraud, R. J. Davis, and M. F. White
c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade
J. Biol. Chem.,
January 24, 2003;
278(5):
2896 - 2902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Park, S. R. Paulsen, S. R. Gammon, K. J. Mustard, D. G. Hardie, and W. W. Winder
Effects of thyroid state on AMP-activated protein kinase and acetyl-CoA carboxylase expression in muscle
J Appl Physiol,
December 1, 2002;
93(6):
2081 - 2088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-y. Qiao, R. Zhande, T. L. Jetton, G. Zhou, and X. J. Sun
In Vivo Phosphorylation of Insulin Receptor Substrate 1 at Serine 789 by a Novel Serine Kinase in Insulin-resistant Rodents
J. Biol. Chem.,
July 12, 2002;
277(29):
26530 - 26539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakamoto and L. J. Goodyear
Exercise Effects on Muscle Insulin Signaling and Action: Invited Review: Intracellular signaling in contracting skeletal muscle
J Appl Physiol,
July 1, 2002;
93(1):
369 - 383.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|